Xencor Inc. Stock
€20.20
Your prediction
Xencor Inc. Stock
Pros and Cons of Xencor Inc. in the next few years
Pros
Cons
Performance of Xencor Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Xencor Inc. | -3.810% | -5.607% | -17.886% | -21.705% | -1.942% | -43.575% | - |
Ironwood Pharmaceuticals | 2.600% | -3.049% | -42.391% | -20.785% | -23.558% | -11.667% | -31.701% |
Novocure Ltd | 0.930% | 7.378% | -10.971% | -75.204% | -6.200% | -87.619% | - |
Iovance Biotherapeutics Inc. | 1.540% | -4.442% | -19.187% | 128.293% | 66.688% | -47.104% | - |
Comments
News
Xencor to Present at Upcoming Investor Conferences
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that company
Xencor Reports Fourth Quarter and Full Year 2023 Financial Results
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for
Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it